Access inclusive support resources

for your eligible

severe asthma

patients

EXPLORE RESOURCES NOW

GB-74958 | March 2026

Intended for UK Healthcare Professionals only

Click here for TEZSPIRE (Tezepelumab) Prescribing Information

Click here for TEZSPIRE (Tezepelumab) Summary of Product Characteristics

GB-74958 | March 2026

Intended for UK Healthcare Professionals only

Click here for TEZSPIRE (Tezepelumab) Prescribing Information

Click here for TEZSPIRE (Tezepelumab) Summary of Product Characteristics

TEZSPIRE PATIENT RESOURCES HERE

GB-74958 | March 2026

Intended for UK Healthcare Professionals only

Click here for TEZSPIRE (Tezepelumab) Prescribing Information

Click here for TEZSPIRE (Tezepelumab) Summary of Product Characteristics

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should be reported to AstraZeneca by visiting http://contactazmedical.astrazeneca.com or by

calling 0800 783 0033.